Viewing Study NCT05704634


Ignite Creation Date: 2025-12-25 @ 2:21 AM
Ignite Modification Date: 2025-12-27 @ 11:46 PM
Study NCT ID: NCT05704634
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-27
First Post: 2023-01-19
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
Sponsor: M.D. Anderson Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module